12:00 AM
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OGX-427: Phase II start

By the end of the quarter, OncoGenex said that the Sarah Cannon Research Institute will begin the double-blind, placebo-controlled, U.S. Phase II Spruce trial to compare IV OGX-427 plus carboplatin and pemetrexed vs. placebo plus carboplatin and...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >